ABSTRACT
The airway epithelium, which lines the conducting airways, is central to the defense of the lungs against inhaled particulate matter and pathogens such as SARS-CoV-2, the virus that causes COVID-19. Recognition of pathogens results in the activation of an innate and intermediate immune response which involves the release of cytokines and chemokines by the airway epithelium. This response can inhibit further viral invasion and influence adaptive immunity. However, severe COVID-19 is characterized by a hyper-inflammatory response which can give rise to clinical presentations including lung injury and lead to acute respiratory distress syndrome, viral pneumonia, coagulopathy, and multi-system organ failure. In response to SARS-CoV-2 infection, the airway epithelium can mount a maladaptive immune response which can delay viral clearance, perpetuate excessive inflammation, and contribute to the pathogenesis of severe COVID-19. In this article, we will review the barrier and immune functions of the airway epithelium, how SARS-CoV-2 can interact with the epithelium, and epithelial-derived cytokines and chemokines and their roles in COVID-19 and as biomarkers. Finally, we will discuss these immune mediators and their potential as therapeutic targets in COVID-19.
Subject(s)
COVID-19 , Pneumonia, Viral , Humans , SARS-CoV-2 , Immunologic Factors , CytokinesABSTRACT
Asphaltenes, among the most complex components of crude oil, vary in their molecular structure, composition, and self-assembly in porous media. This complexity makes them challenging in laboratory characterization methods. In the present work, a novel microfluidic device was designed to access in situ transient, high-fidelity information on asphaltene deposition and dissolution within porous media. The automated microfluidic device features three independent 4.5 µL packed-bed microreactors on the same chip. The deposition of asphaltenes was investigated at five different temperatures (ranging from 25-65 °C) in addition to dissociation with xylenes. Our findings demonstrate a decrease in the dispersity of asphaltene nanoaggregates in the porous media when the deposition temperature is increased. Furthermore, the direct quantification of the dissociation solvent was made possible by in situ Raman spectroscopy. The average occupancy of xylenes and xylene-free porous media (or unrecognized sites) was estimated to be 0.41 and 0.66, respectively. It was observed that asphaltenes deposited at higher deposition temperatures are more difficult to dissociate by xylenes than those deposited at lower temperatures. In order to develop efficient remediation treatments in energy production operations, the convoluted behaviours of asphaltenes in porous media must be understood on a molecular level. Automated microfluidic systems have the potential to streamline treatment designs, improve their efficiency, and enable the design of green chemistry in conventional energy production operations.
ABSTRACT
BACKGROUND: Agents promoting oligodendrocyte precursor cell differentiation have the potential to restore halted and/or delayed remyelination in patients with multiple sclerosis. However, few therapeutic targets have been identified. The objective of this study was to identify novel targets for promotion of remyelination and characterize their activity in vitro and in vivo. METHODS: A high-content screening assay with differentiation of primary rat oligodendrocyte precursor cells was used to screen GSK-proprietary annotated libraries for remyelination-promoting compounds. Compounds were further validated in vitro and in vivo models; clinical relevance of target was confirmed in human post-mortem brain sections from patients with MS. RESULTS: Of ~1000 compounds screened, 36 promoted oligodendrocyte precursor cell differentiation in a concentration-dependent manner; seven were histamine receptor-3 (H3R) antagonists. Inverse agonists of H3R but not neutral antagonists promoted oligodendrocyte precursor cell (OPC) differentiation. H3R was expressed throughout OPC differentiation; H3R expression was transiently upregulated on Days 3-5 and subsequently downregulated. H3R gene knockdown in OPCs increased the expression of differentiation markers and the number of mature oligodendrocytes. Overexpression of full-length H3R reduced differentiation marker expression and the number of mature cells. H3R inverse agonist GSK247246 reduced intracellular cyclic AMP (cAMP) and downstream cAMP response element-binding protein (CREB) phosphorylation in a dose-dependent manner. Histone deacetylase (HDAC-1) and Hes-5 were identified as key downstream targets of H3R during OPC differentiation. In the mouse cuprizone/rapamycin model of demyelination, systemic administration of brain-penetrable GSK247246 enhanced remyelination and subsequently protected axons. Finally, we detected high H3R expression in oligodendroglial cells from demyelination lesions in human samples of patients with MS, and validated a genetic association between an exonic single nucleotide polymorphism in HRH3 and susceptibility to multiple sclerosis. CONCLUSIONS: From phenotypic screening to human genetics, we provide evidence for H3R as a novel therapeutic target to promote remyelination in patients with multiple sclerosis.
